Results from a prospective study bolster confidence that a negative adenosine perfusion contrast MR test means patients have a good chance of surviving the next six months without major heart problems.
Results from a prospective study bolster confidence that a negative adenosine perfusion contrast MR test means patients have a good chance of surviving the next six months without major heart problems.
Dr. David Hardung from St. Marien Hospital in Bonn, Germany, surveyed the medical experience of 432 patients with negative adenosine stress tests or evidence of minor perfusion deficits involving less than 25% transmural enhancement of the myocardial wall. The event-free survival rate after 267 days was 98.8%. One cardiac death was reported from nonischemic dilated cardiomyopathy. No incidences of myocardial infarction or acute coronary syndrome occurred, but four cases of significant coronary artery disease were identified among 36 patients who underwent coronary angiography in the follow-up period.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.